Potential Association of Holidays on Internationalized Normalized Ratio in Warfarin-Users at a Multidisciplinary Clinic.
Anticoagulation
Cardiology
International normalized ratio
Warfarin
Journal
Cardiology research
ISSN: 1923-2829
Titre abrégé: Cardiol Res
Pays: Canada
ID NLM: 101557543
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
08
11
2022
accepted:
06
01
2023
entrez:
10
3
2023
pubmed:
11
3
2023
medline:
11
3
2023
Statut:
ppublish
Résumé
Warfarin is approved by the United States Food and Drug Administration for numerous clinical indications. The effectiveness of warfarin is highly dependent on the time-in-therapeutic range based on the international normalized ratio (INR) goal, which may be altered by changes in diet, alcohol intake, concomitant drugs, and travel, all of which are prevalent during the holidays. At this time, there are no published studies assessing the impact of holidays on INR in warfarin-users. A retrospective chart review was conducted on all adult patients taking warfarin and managed at a multidisciplinary clinic. Patients were included if they were taking warfarin at home regardless of indication for anticoagulation. The INR pre- and post-holiday was assessed. Of a total of 92 patients, the mean age was 71.5 ± 14.3 years, and most patients were on warfarin with an INR goal of 2 - 3 (89%). There were significant differences in INR before and after Independence Day (2.55 vs. 2.81, P = 0.043) and Columbus Day (2.39 vs. 2.82, P < 0.001). The remaining holidays showed no significant differences in INR before and after each respective holiday. There may be factors related to Independence and Columbus Day that are increasing the level of anticoagulation in warfarin-users. Although the mean post-holiday INR values, in essence, maintained within the typical target of 2 - 3, our study underscores the specialized care that is warranted in higher risk patients to prevent a continued increase in INR and subsequent toxicities. We hope our results would be hypothesis-generating and aid in the development of larger, prospective evaluations to validate the findings of our present study.
Sections du résumé
Background
UNASSIGNED
Warfarin is approved by the United States Food and Drug Administration for numerous clinical indications. The effectiveness of warfarin is highly dependent on the time-in-therapeutic range based on the international normalized ratio (INR) goal, which may be altered by changes in diet, alcohol intake, concomitant drugs, and travel, all of which are prevalent during the holidays. At this time, there are no published studies assessing the impact of holidays on INR in warfarin-users.
Methods
UNASSIGNED
A retrospective chart review was conducted on all adult patients taking warfarin and managed at a multidisciplinary clinic. Patients were included if they were taking warfarin at home regardless of indication for anticoagulation. The INR pre- and post-holiday was assessed.
Results
UNASSIGNED
Of a total of 92 patients, the mean age was 71.5 ± 14.3 years, and most patients were on warfarin with an INR goal of 2 - 3 (89%). There were significant differences in INR before and after Independence Day (2.55 vs. 2.81, P = 0.043) and Columbus Day (2.39 vs. 2.82, P < 0.001). The remaining holidays showed no significant differences in INR before and after each respective holiday.
Conclusions
UNASSIGNED
There may be factors related to Independence and Columbus Day that are increasing the level of anticoagulation in warfarin-users. Although the mean post-holiday INR values, in essence, maintained within the typical target of 2 - 3, our study underscores the specialized care that is warranted in higher risk patients to prevent a continued increase in INR and subsequent toxicities. We hope our results would be hypothesis-generating and aid in the development of larger, prospective evaluations to validate the findings of our present study.
Identifiants
pubmed: 36896230
doi: 10.14740/cr1448
pmc: PMC9990547
doi:
Types de publication
Journal Article
Langues
eng
Pagination
38-44Informations de copyright
Copyright 2023, Ryu et al.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Thromb Haemost. 1994 Jun;71(6):802-3
pubmed: 7974354
J Thromb Haemost. 2008 Feb;6(2):284-90
pubmed: 18031295
Can J Kidney Health Dis. 2017 Oct 20;4:2054358117735532
pubmed: 29093823
Medicine (Baltimore). 2015 Dec;94(50):e2233
pubmed: 26683937
J Am Soc Nephrol. 2009 Apr;20(4):872-81
pubmed: 19297555
Pathophysiol Haemost Thromb. 2002 Jul-Aug;32(4):151-4
pubmed: 12759514
Chest. 2007 May;131(5):1277-9
pubmed: 17494777
BMJ. 2018 Dec 12;363:k4811
pubmed: 30541902
Am J Med. 2017 Sep;130(9):1092-1098.e2
pubmed: 28454906
Chest. 2016 Apr;149(4):951-9
pubmed: 26378611
J Thromb Haemost. 2013 Jun;11(6):1043-52
pubmed: 23581252
High Alt Med Biol. 2006 Spring;7(1):39-46
pubmed: 16544965
BMC Nephrol. 2016 Oct 21;17(1):157
pubmed: 27769175
JAMA Netw Open. 2020 Apr 1;3(4):e202175
pubmed: 32250434
J Am Coll Clin Pharm. 2021 Apr;4(4):459-464
pubmed: 33821238
Circulation. 2004 Dec 21;110(25):3781-8
pubmed: 15596560
Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221103578
pubmed: 35642259
BMJ. 2018 Dec 10;363:k4481
pubmed: 30530782
Chest. 2006 Nov;130(5):1385-9
pubmed: 17099014
Lancet. 2012 Jan 28;379(9813):322-34
pubmed: 22137798
BMJ Open. 2018 Jan 29;8(1):e016980
pubmed: 29382672
Sci Rep. 2021 Sep 29;11(1):19376
pubmed: 34588561
Chest. 2001 Jan;119(1 Suppl):8S-21S
pubmed: 11157640